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ProPhylaxis of Venous Thromboembolism 
in orThoPaedic surgery
Luiz Eugênio Garcez Leme1, Guilherme Turolla Sguizzatto2
ABSTRACT
The relevance of prophylaxis of venous thromboembolism and 
its complications in orthopedic surgery is increasingly signifi-
cant. This review discusses the pathophysiology of thrombus 
formation in general and orthopedic surgery, its incidence, pre-
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disposing factors and complications. It also presents an updated 
presentation and critique of prophylaxis currently available in 
our environment.
Keywords – Venous Thrombosis/prevention & control; 
Embolism/prevention & control; Orthopedics
INTRODUCTION
Prophylaxis of venous thromboembolism (VTE) 
and pulmonary embolism (PE) in orthopedic surgery, 
particularly in arthroplasties, continues to stir up con-
siderable debate among health professionals, not only 
in Brazil, but worldwide.
This reality is part of an increasing awareness of 
two aspects: on one hand is the need to prevent avoi-
dable complications with catastrophic repercussions, 
as can be the case with VTE and PE, and on the other, 
care to minimize the possible risks of bleeding asso-
ciated with surgical procedures. 
Studies in 1992 to compare enoxaparin and placebo 
in arthroplasties inform us that in the group submitted 
to prophylaxis, the presence of DVT detected by phle-
bography was 17%, while in the placebo group, it was 
53% (p < 0.0001). On the other hand, the incidence of 
more severe bleeding occurred in 6% of the placebo 
group, and in 8% of the enoxaparin group, without 
statistical significance (p = 0.71)(1).
In some countries, like the United States, this re-
ality has created increasingly rigid demands, in the 
requirement to adopt mechanisms to protect patients 
in conditions of risk.
In fact, thromboembolic phenomena represent the 
more common complications in arthroplasties, inclu-
ding complications in the arteries(2) and, in particular, 
in the veins, which are the greatest cause of death in 
the first three months after surgery, representing more 
than 50% of postoperative mortality(3). 
This condition leads to a growing level of demand 
that is incorporated into preventative care in major 
orthopedic surgeries in the United States(4) and at the 
same time, in the large medical centers.
Thrombosis can occur as part of the natural phy-
siological process. In normal situations, there is a 
balance between factors that hinder and those that 
promote clotting. An alteration to this balance can 
lead to untimely clotting. On the other hand, clotting 
failures can lead to hemorrhage. 
the virchow’s triad 
More than 150 years ago, Rudolf Virchow apud 
Merli(5) described the triad of factors responsible 
for thrombogenesis. These include: venous stasis, 
endothelial damage, and hypercoagulation. As can 
be seen, these three factors are closely linked to or-
thopedic procedures, particularly major ones, like 
arthroplasties. 
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the clotting cascade 
The clotting mechanism consists of self-regula-
ting processes that result in the production of a fibrin 
thrombus. These processes are controlled by inactive 
cofactors that, when activated, promote or accelerate 
clotting. These processes usually occur on the surfa-
ces of the platelets or macrophages, or in the endothe-
lial cells, and are initiated by two specific pathways: 
extrinsic and intrinsic. 
The extrinsic pathway is initiated as a result of 
activation of tissue lipoproteins resulting from me-
chanical injuries such as trauma and/or surgery. 
The intrinsic pathway involves circulating plasma 
factors.
Both pathways are found at the level of factor X, 
transformed into factor Xa. This factor promotes the 
conversion of prothrombin into thrombin (factor II), 
which, in turn, transforms the fibrinogen into fibrin, this 
being the key step for the formation of the thrombus. 
The plasmin digests the fibrin, as well as inactiva-
ting the V and VIII factors and fibrinogen, restoring 
normal blood flow. 
There are three anticlotting mechanisms that 
prevent the formation of thrombi: antithrombin III 
(ATIII), C and S proteins, and the extrinsic pathway 
inhibition (tissue factor).
When surgery and/or trauma occur, there is a de-
crease in circulating ATIII, instigating the clotting 
process. Studies have shown that this decrease in 
ATIII is greater, and remains for longer in total hip ar-
throplasties (THA) than in cases of general surgery. In 
patients with DVT diagnosed after surgery, the ATIII 
levels were low(6). 
localization of the thrombi
The majority of thrombi may develop in the deep 
veins of the calf, rising from here to the thigh; howe-
ver, in up to 30% of clots, the primary origin may be 
higher up, in the iliofemoral venous segment, inde-
pendent of any thrombi originating in the calf veins.
In terms of relationship with the operated limb, 
80% of thromboses originate here, while in up to 20% 
of cases, they may originate in the healthy limb. 
Most clots in the calf are small, and clinically in-
significant. Likewise, proximal vein thrombosis may 
not be occlusive and asymptomatic, and in some ca-
ses, it regresses spontaneously, without any adverse 
effects. Meanwhile, there is an important link between 
proximal deep vein thrombosis and pulmonary embo-
lism, and also between silent, non-occlusive thrombi 
and symptomatic or fatal pulmonary embolism(7,8).
the risks of venous thromboembolism in hospi-
talized patients
The risk of development of DVT in hospitalized 
patients is notably high, ranging from 10 to 20% in 
patients with clinical disorders and 80% or more in 
patients with spinal cord injury, or critical patients(9).
Among hospitalized patients and those submitted to 
surgery, patients who have undergone surgery for can-
cer, or orthopedic surgery, are at higher risk (Table 1).
venous thromboembolism and orthopedic surgery 
The nature of orthopedic disorders and diseases, 
such as trauma, arthroplasties, particularly of the hip 
and knee, create a higher risk for the occurrence of 
venous thromboembolism.
The positioning of the limb during surgery, locali-
zed postoperative edema, and limitations in mobility 
immediately after surgery, all play a role in venous 
stasis and the consequent reduction of blood flow(10). 
During surgery, manipulation of the limb, heat 
reaction resulting from the use of cement, and other 
aggressions can also activate thrombogenic factors 
that will manifest tropism for areas of vascular lesion 
and stasis(11). On the other hand, blood loss can reduce 
the antithrombin III levels and inhibit the endogenous 
fibrinolytic system, enabling the formation and growth 
of thrombi(12,13), at all levels.
Table 1 – Absolute risk of DVT in hospitalized patients.
Group of patients Prevalence (%) DVT
Clinical patients 10–20
General surgery 15-40
Major gynecological surgery 15-40
Major urological surgery 15-40
Neurosurgery 15-40
Stroke 20-50
Arthroplasties of the hip or knee 40-60
Spinal cord injury 60-80
Major trauma 40-80
Critical patients 10-80
Rates based on DVT in patients not receiving thromboprophylaxis.
Source: Adapted from Geerts WH, et al. Prevention of venous thromboembolism: the Seventh ACCP 
Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(Suppl 3):338S-400S.
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Figure 1 – Relative risks of pulmonary embolism and deep vein thrombosis 
over time.
Adapted from Sweetland S, et al. Duration and magnitude of the postoperative risk of venous 
thromboembolism in middle aged women: prospective cohort study. BMJ. 2009;339:b4583.
Figure 2 – Incidence of events/days after primary arthroplasties of the hip 
or knee (Kaplan-Meyer). 
Adapted from White RH, et al. Arch Intern Med. 1998;158:1525-31.
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During their evolution, many asymptomatic 
thrombi regress spontaneously without treatment, 
without extending this thrombus or evolving to PE 
or post-thrombotic syndrome (PTS)(14). Only one 
in eight thrombi identified by the venography will 
evolve to symptomatic DVT(15), while proximal 
thrombi (above the poplipteal vein) have a higher 
likelihood of being symptomatic. However, around 
10% of deaths occurring after THA are related to PE. 
It is known that between 3 and 4% of all symptomatic 
cases of VTE evolve to fatal PE(16).
Compared with other disorders that lead to hospita-
lization of patients, the rate of DVT among high-risk 
orthopedic patients is substantially higher, including 
in patients hospitalized for clinical complaints or even 
other surgeries. A study by Geerts et al(17) showed 
that patients who did not use prophylaxis and were 
submitted to THA had a rate of DVT of 50-60%, of 
which 20-30% were proximal. The total incidence 
was even higher in patients after TKA, with a rate of 
60-85% of total DVT, but with a lower rate of proxi-
mal DVT of 9-20%. Patients with hip fractures had 
a total rate of DVT of 30-60%, of which up to 36% 
were proximal. In these same series, the risk of fatal 
PE was 0.4-12.9% (Table 2).
Another important data is presented to us by Falck-
-Ytter et al(18), who, in their work, give graphs compa-
ring the cumulative evolution of VTE in the first 90 
days postoperative, comparing non-prophylaxis with 
the use of LMWH.
From a temporal perspective, studies located the 
peak risk of DVT and PE at around the third and four-
th weeks postoperative, for hospitalized patients(19) 
(Figure 1). 
Other cohort studies suggest that the peak mani-
festation of DVT occurs around the first month, and 
can remain up to the 12th week(20).
An analysis of 11,607 patients submitted to to-
tal hip arthroplasty (THA) between 1976 and 1985 
showed a relative risk of 2.85 for the occurrence 
of DVT and PTE as the cause of death in the first 
three months postoperative, when compared with the 
remainder of the year(21).
When primary arthroplasties of the hip and knee 
were studied, the DVTs appeared to be more prevalent 
in the first group(22) (Figure 2).
Pulmonary thromboembolism (PtE)
Pulmonary thromboembolism may be the most 
feared complication of VTE. Its presentation is va-
ried, and can range from fulminant conditions to mild 
dyspnea, or even a total absence of symptoms. The 
rate of lethality accompanies this heterogeneity, ran-
ging from more than 60% to less than 1% of cases(23).
Diagnosis is often difficult due to the variable 
symptoms, and the use of algorithms may be use-
ful(24) (Figure 3).
Once the diagnosis has been made, treatment 
should begin immediately, and should clearly follow 
distinct parameters from those used for prophylaxis, 
Table 2 – Risk of VTE after orthopedic surgery in patients who did not 
receive prophylaxis.
Total DVT Proximal DVT Total PTE Fatal PTE
Surgery  % % % %
TKA 41-85 05-22 1.5-10 0.1-1.7
THA 42-57 18-36 0.9-28 0.1-2.0
Hip fracture 46-60 23-30 03-11 0.3-7.5
Adapted from Geerts WH, et al. Prevention of Venous Thromboembolism: American College of 
Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;381S-453S.
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Figure 3 – Diagnostic algorithm for suspected PTE in patient without 
hypotension or shock. 
Adapted from Konstantinides KS. Acute pulmonary embolism. N Engl J Med. 2008;395:2804-13.
Figure 4 – Treatment regimen of PTE. 
Adapted from Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med. 2010;363:266-74.
Clinical Probability Score
Signs and symptoms of VET 3.0
HR > 100 bpm/min 1.5
Recent immobilization/surgery < 4 weeks 1.5
Previous VET or PET 1.5
Hemoptysis 1.0
Cancer 1.0
More evident PET/other diagnoses 3.0 
Low score (< 2.0) or 
intermediate (2.0-6.0)
High score (> 6.0)
Dimer D (high sensitivity) Vascular CTPositivo
Negative
Do not treat Treat
Without pulmonary embolism Pulmonary embolism 
confirmed
 ○NFH
 ○LMWH 
 ○Fondaparinux
 ○Thrombolysis 
 ○Percutaneous mechanical 
embolectomy
 ○Surgery
 ○Vitamin K antagonists
 Vitamin K antagonists
INR 2.0-3.0
Vitamin K antagonists
INR 2.0-3.0 or 1.5-1.9
Initial treatment Prolonged treatment Extended treatment
5 days
3 months
Indefinite
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with an initial phase of five days, which may extend 
to three months, or in cases of high risk of relapse, 
for the remainder of the patient’s life(24) (Figure 4).
other complications of dvt
PTE is not the only complication of DVT. A pa-
tient with VTE can evolve to post-thrombotic syn-
drome (PTS), a circumstance characterized by vein 
ulceration by stasis, severe chronic pain in the leg, 
and untreatable edema of the ankle. In a study of 355 
patients with DVT, the incidence of PTS was 17.5% 
after one year, 22.8% after two years, and 28% after 
five years(25). 
Prophylaxis
Based on all the above mentioned characteristics, 
it is clear that prophylaxis of DVT is necessary in 
orthopedic procedures, and particularly, though not 
exclusively in arthroplasties.
Within this perspective, tools for raising awareness 
among professionals to follow the guidelines can play 
an important role(26). 
Orthopedic surgeons have generally demonstrated 
good awareness in the use of thromboprophylaxis, 
compared with professionals of other medical special-
ties. In 2008, a questionnaire to members of the Ame-
rican Association of Hip & Knee Surgeons (AAHKS) 
showed that the majority of those questioned (> 80%) 
agreed with the preoperative assessment protocols of 
risk factors for VTE, and with postoperative prophyla-
xis (pharmacological and mechanical). Furthermore, 
28% reported that they had changed their prophylactic 
practice in the last five years, in accordance with the 
ACCP and/or AAOS(27).
A recent questionnaire of the American Associa-
tion of Hip and Knee Surgeons indicated that 100% of 
their members used some method of prophylaxis for 
DVT. In 2003, the result (HIP and KNEE Registry) 
showed that one or more types of prophylaxis were 
carried out in 99% of patients. Approximately 89% 
of THA patients and 91% of TKA patients received 
prophylaxis according to the recommendations of the 
7th ACCP(20). 
In our context, in hospitals of São Paulo, a study 
involving 1454 patients (589 surgical and 865 
clinical) showed that despite the existence of various 
guidelines, thromboprophylaxis is not carried out 
appropriately: high-risk patients are undertreated, and 
low-risk patients are overtreated(28). 
This circumstance needs to be changed to ensure 
patients receive adequate treatment for the prevention 
of thromboembolism. 
vtE risk assessment
A simplified risk assessment can be useful in the 
initial clinical assessment of the patient.
The Diretrizes (Guidelines) project, carried out in 
partnership with the Brazilian Medical Association 
and the Federal Council of Medicine, gives a clear 
picture of the risk assessment of DVT, and possible 
measures to be taken(29) (Figure 5). 
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Low risk
•	 Operations in patients 
aged under 40 years, 
without other risk 
factors;
•	 Smaller operations (of 
less than 30 minutes 
and without the need 
for prolonged rest) in 
patients aged over 40 
years without any other 
risk except for age;
•	 Minor trauma
Moderate risk
•	 Major surgery 
(general, urological 
or gynecological) 
in patients from 40 
to 60 years, without 
additional risk factors;
•	 Surgery in patients 
aged under 40 years 
taking estrogens.
High risk
•	 General surgery in patients aged 60 or over; 
•	 General surgery in patients aged 40-60 years 
with additional risk factors;
•	 Major surgery in patients with a previous 
history of DVP or PE or thrombophilia;
•	 Major amputations;
•	 Major orthopedic surgeries;
•	 Major surgeries in patients with malignant 
neoplasms;
•	 Major surgeries in patients with other states of 
hypercoagulability;
•	 Multiple traumas with fractures of the pelvis, 
hip, or lower limbs.
Revaluate daily for the presence of venous thrombosis
Comments:
•	 The protocol for prophylaxis of venous thrombosis of the SBACV (Brazilian Society of Angiology and 
Vascular Surgery, in Portuguese) (Caiafa, 2001) can assist in the classification of risk and definition of 
prophylaxis.
•	 Patients with risk of hemorrhage should use anti-thrombotic elastic stockings or intermittent pneumatic 
compression.
•	 LMWHs are not interchangeable. Therefore, they should not be alternated in the same treatment.
•	 Subcutaneous injections should be administered in the upper and lateral quadrants of the abdomen, 
alternating the side with each injection.
Risk assessment
Low risk
•	 Movement in the bed
•	 Early walking
Moderate risk
•	 Heparin, SC, 5000 UI, 
every 12 hours
 t Initiate 2-4 hours before 
surgery if general 
anesthesia
 t Initiate 1 hour after 
puncture if blockade
•	 LMWH, SC, smaller dose, 
1x daily
 t Initiate 2 hours before 
surgery if general 
anesthesia 
 t Initiate 12 hours before 
surgery if blockade
•	 Higher risk of hemorrhage: 
anti-thrombotic stockings
High risk
•	 LMWH – SC, higher prophylactic dose 
1x daily
 t Initiate 12 hours before surgery
•	 Heparin SC – 5000 UI, every 8 hours
 t Initiate 2 hours before surgery if 
general anesthesia
 t Initiate 1 hour after puncture if 
blockade
•	 High risk of hemorrhage: intermittent 
pneumatic compression.
methods of prophylaxis
Although the use of low-molecular-weight heparin 
(LMWH) or non-fractionated heparins (NFH) repre-
sent the most common model of prophylaxis in our 
context, other alternatives can be listed, and critically 
considered. Initially, we can divide prophylaxis into 
mechanical and pharmacological.
MECHANICAL PROPHyLAxIS
Early walking
The most simple and possibly the most applicable 
method of prevention of venous stasis and DVT is, 
where possible, early walking. 
Early walking is associated with a lower incidence 
of post-THA symptomatic VTE(30). Also, stimulation 
of early walking associated with motor physiotherapy 
after hip fracture can be associated with an early re-
turn to the community, shorter hospitalization time, less 
complications, and low mortality after six months(31).
mechanical methods
Methods such as graduated elastic compression 
stockings (GECS), intermittent pneumatic compression 
(IPC), and plantar venous pump (PVP) increase blood 
flow and reduce venous stasis. These methods have the 
benefit that they have no risk of bleeding, presenting 
advantages in patients with an increased risk of 
bleeding. On the other hand, these methods may be 
difficult to implement or maintain, due to the limited 
movement of the patient and the discomfort they can 
bring. They are also contraindicated in situations 
such as exposed fracture, infection of the lower 
limbs, peripheral arterial insufficiency, severe cardiac 
insufficiency, and ulceration of the lower limbs.
The start of prophylaxis with mechanical methods 
may be the method of choice in patients with a high 
risk of bleeding; however, when this risk is temporary, 
prophylaxis should be initiated, by pharmacological 
means, as soon as the risk decreases. Another factor 
to be considered is irregular use of these methods, and 
training in their correct use, and they should only be 
discontinued for very short periods (during walking 
or when using the bathroom). 
Current data (9th ACCP) suggest the use of me-
chanical methods in addition to pharmacological pro-
phylaxis during hospitalization, in patients with a high 
risk for DVT in major orthopedic surgeries(18). 
Pharmacological prophylaxis
Until a few years ago, heparin and warfarin were, 
in practice, the only drugs used in anticoagulant 
therapy. They are widely available, cheap, effective, 
and contain specific antidotes. However, they are 
considered problematic due to the need for their 
careful monitoring.
Warfarin has a slow onset of action, interacts with 
various drugs and foods, has a narrow therapeutic 
window, and has initial paradoxal prothrombic action. 
Heparin requires monitoring when used for thera-
peutic purposes, and is associated with the develop-
ment of thrombosis and bleeding, a condition known 
as heparin-induced thrombocytopenia (HIT).
Platelet antiaggregants: acetylsalicylic acid (AsA) 
and clopidogrel 
Acetylsalicylic acid and clopidogrel are medica-
tions with permanent and temporary platelet aggre-
gation inhibiting action, respectively.
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The use of ASA as a prophylactic agent for VTE is 
controversial. Although ASA is more effective than pla-
cebo in the prophylaxis of VTE the 9th ACCP does not 
recommend its use as the sole prophylactic method in or-
thopedic surgeries, due to the lack of definitive evidence 
of its action, and the possibility of gastric alterations(18). 
While platelet antiaggregants are of little use in the 
prevention of venous thrombosis, they are essential in 
the prevention of arterial thrombosis, and can represent 
a risk in orthopedic procedures.
In fact, the need to deal with patients using ASA and 
clopidogrel in the prevention of coronary obstruction, 
and the use of pharmacological stents, may represent a 
challenge for the orthopedic team, since in these cases, 
suspending the medication can pose a risk of thrombosis 
of the stent. In this condition, the risks of suspending 
clopidogrel should we weighed against the risk of in-
creased bleeding that is generated by double antiplatelet 
therapy(32).
If the risk of bleeding is too high, the suspended anti-
platelet therapy should be resumed as soon after surgery 
as is reasonably possible. 
warfarin 
Warfarin, through vitamin K blockade, is an inhibitor 
of gamma-carboxylation of various blood clotting fac-
tors (factors II, VII, IX, X, and proteins C and S). It does 
not act on the circulating clotting factors, only on their 
synthesis in the liver, which explains its delayed effect.
Although widely used in North America, here in Bra-
zil, warfarin is little used as prophylaxis in orthopedic 
surgery, mainly due to its therapeutic variability, wide 
drug interactions, food interactions, and the need for 
laboratory monitoring.
When used, warfarin depends on the control of pro-
thrombin activity through the measurement of the INR 
(International Normalized Ratio).
As an undesirable effect, warfarin presents, from the 
onset, a slight procoagulant effect, which may require 
concomitant use of heparin in the first 72 hours.
tecarfarin
Tecarfarin is a recent oral anticoagulant, of the vitamin 
K epoxide-reductase family of antagonists. Unlike warfa-
rin, it is metabolized by esterases, and not by the cytochro-
me P450 system, thereby avoiding drug interactions. On 
the other hand, it appears to be more stable to control by 
the INR than warfarin. It is currently in phase III clinical 
trials, and is not yet available here in Brazil(33).
Non-fractionated heparin (NFH) 
Heparin is an activator of the blood enzyme anti-
thrombin III. This enzyme inhibits various coagulation 
factors (II, IX and X) and more significantly, thrombin, 
which forms the fibrin thrombus. Non-fractionated hepa-
rin (NFH) is used in low doses by the subcutaneous (SC) 
route, which may be 10,000ui SC every 12 hours, or 
5,000ui SC every 8 hours. One of the most feared adver-
se effects is heparin-induced thrombocytopenia (HIT), 
in which there is formation of anti-heparin antibodies/
platelet factor, plateletopenia, with prothrombotic effect, 
which can develop bleeding, thrombosis and embolisms, 
and even death. When there is suspicion of HIT, heparin 
should be suspended immediately.
low-molecular-weight heparin (lmWH) 
This is obtained through the depolymerization of 
heparin and acts, mainly, blocking the factor Xa. It 
can be used subcutaneously, generally in a single daily 
application, without requiring laboratory monitoring. 
This means it can be applied safely and effectively in 
the patient’s home. Currently, the most commonly used 
drugs in Brazil are: 
• enoxaparin in the presentations of 20 mg (used in pa-
tients with creatinine clearance > 30 ml/min) or 40 mg, 
the dosage more commonly used as prophylaxis in or-
thopedic surgeries; and
• dalteparin in the 2,500 UI and 5,000 UI presentations.
Despite the possibility of developing HIT, various stu-
dies suggest that the incidence of HIT during prophylaxis 
with LMWH is lower when compared with NFH. Due to 
its safety and efficiency, enoxaparin is used today as gold 
standard for the development of new anticoagulant drugs.
fondaparinux
Fondaparinux is a pentasaccharide, whose anti-
thrombotic activity is the result of selective inhibition of 
the factor Xa mediated by antithrombin III (ATIII). The 
neutralization of factor Xa interrupts the blood clotting 
cascade, thereby inhibiting the formation of thrombin and 
the development of the thrombus.
As a benefit over other injectable presentations, it does 
not inactivate thrombin (activated factor II), it has no effect 
on the platelets, and it does not cross-react with the serum 
of patients with heparin-induced thrombocytopenia.
A total of 144,806 patients were included in a study 
that showed a lower incidence of VTE with fondapari-
nux (1.5%), compared with enoxaparin (2.3%), dalteparin 
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(2.1%) and NFH (4.2%). Significantly fewer patients in 
the fondaparinux group had some episode or were read-
mitted to hospital due to an episode of VTE, compared 
with those taking other medications(34).
In patients with lowered renal function, particularly el-
derly diabetic patients and those with a high risk of bleeding, 
the dose of LMWH or fondaparinux should be reduced. 
New anticoagulant drugs
a) rivaroxaban
Rivaroxaban is a highly selective, direct inhibitor of 
factor Xa, and is available by oral administration. The 
inhibition of factor Xa interrupts the intrinsic and ex-
trinsic pathways of the clotting cascade, inhibiting the 
formation and development of thrombin. Rivaroxaban 
does not inhibit thrombin (activated factor II) and has 
no effect on the platelets(35). 
More than 9,500 patients (7,050 in THA and 2,531 in 
TKA) were evaluated in randomized, phase III, double-
-blind clinical trials known as the RECORD-programme. 
The dose used was rivaroxaban 10 mg, initiated up to 6 
hours of closure of the surgical wound, compared with 
enoxaparin 40 mg SC, initiated 12 hours before surgery. 
Total DVT occurred in 79 out of 824 patients (9.6%) 
who received rivaroxaban and in 166 out of 878 (18.9%) 
who received enoxaparin (absolute risk reduction, 9.2%); 
proximal DVT occurred in nine out of 908 patients 
(1.0%) with rivaroxaban and in 24 out of 925 (2.6%) 
with enoxaparin (absolute risk reduction, 1.6%). Symp-
tomatic events occurred less frequently with rivaroxaban 
than with enoxaparin (p = 0.005). Major bleeding in 
0.6% of the patients of the rivaroxaban group and 0.5% 
of the patients of the enoxaparin group. The incidence of 
adverse effects, the majority gastrointestinal, was 12.0% 
with rivaroxaban and 13.0% with enoxaparin.
b) dabigatran
Dabigatran etexilate is a direct oral inhibitor of 
thrombin. Its efficacy was analyzed in studies that 
compare dabigatran etexilate (220 or 150 mg per day) 
with enoxaparin. The first study(36) involved a total 
of 2101 patients submitted to TKA (150 mg or 220 
mg once daily) and the second(37) involved a total of 
3494 patients submitted to THA. In both studies, the 
main parameter of efficacy was the number of VTE 
or deaths by any cause during the treatment period.
In both studies, dabigatran etexilate was as effec-
tive as enoxaparin in preventing VTE or death.
Recently, however, studies have reported a rela-
tionship between the use of dabigatran and an increase 
of coronary events, including myocardial infarction(38), 
which places its use in doubt, pending further studies.
Current prophylaxis proposals
The ninth edition (2012) of the evidence-based 
clinical guidelines of the American College of Chest 
Physicians(18) contains guidelines for prevention in 
major orthopedic surgery, namely:
Elective arthroplasty of the hip or knee 
Extended use after discharge up to the 35th day after 
surgery of one of the following: LMWH and alternati-
vely, fondaparinux, apixaban, dabigatran, rivaroxaban, 
NFH, Vitamin K antagonist, Aspirin® (polemic).
*During hospitalization: intermittent pneumatic compression (more 
than 18 hours/day).
Hip fracture 
Extended use after discharge up to the 35th day after 
surgery of one of the following: LMWH, and alternative-
ly, fondaparinux, NFH, Vitamin K antagonist, Aspirin® 
(polemic).
*During hospitalization: intermittent pneumatic compression (more 
than 18 hours/day).
Extended prophylaxis
In a study from 1998, 19,586 THA and 24,059 TKA 
with cumulative incidence of VTE, the mean time to diag-
nosis was 2.8% and 2.1, respectively; after surgery, it was 
17 days for THA and seven days for TKA. Although 88% 
of these patients received prophylaxis while hospitalized, 
76% and 74% of the thromboembolic events were diagno-
sed after discharge from hospital, and only 32% of these 
patients continued with the prophylaxis at home(8).
A multicenter trial with 15,020 patients showed 
that those who received LMWH continued throughout 
every phase of the trial, i.e. even after discharge. 
However, approximately 37% of patients submitted to 
THA who initially received LMWH, did not continue 
to receive it after discharge, which is currently 
a recommendation of the ACCP Guidelines. By 
contrast, the duration of prophylaxis with warfarin 
with or without IPC was shorter(9). 
Currently, the recommendation is to maintain pro-
phylaxis for VTE in patients submitted to THA and in 
the postoperative phase of fracture of the femur for at 
least four weeks, and in patients submitted to TKA, for 
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at least ten days. Patients who have suffered spinal cord 
trauma, with total lesion of the spinal cord should re-
ceive anticoagulation medication for at least six weeks.
Anesthetic blockade
Systematic reviews have demonstrated that neuraxial 
blockade reduced cardiac and pulmonary morbidity and 
bleeding when compared with general anesthesia. Pain 
control and patient satisfaction are also improved with 
this method. Meanwhile, in patients using anticoagulant 
medications, a rare, but more devastating complication 
can occur: epidural or spinal cord hematoma(19).
Some care should be taken to increase the safety of 
the anesthetic blockade in patients receiving or who will 
receive anticoagulants. For example: contraindicating 
anesthetic blockade in patients with clotting alterations. 
Anti-inflammatories and ASA do not appear to incre-
ase the risk of subdural or spinal cord hematoma. 
Clopidogrel should be suspended for at least seven 
days prior to the blockade.
INDICATION 
total knee arthroplasty (tKA)
For patients submitted to TKA, the following should 
be used: 
• enoxaparin 40 mg SC 1x daily, initiating up to 12 
hours pre- or postoperative. Or if the above is not 
possible:
• dalteparin 5.000ui SC 1x daily, initiating up to 12 
hours postoperative. 
• dabigatran 110 mg, oral route, initiated 1 to 4 hours 
postoperative, 24 hours after the first dose, two 110 
mg tablets together. 
• rivaroxaban 10 mg, oral route, 1x daily, initiated 6 
to 12 hours postoperative. 
• Vitamin K blockers.
Prophylaxis should be used for at least 10 to 14 
days, possibly extending to 35 days, depending on 
the associated risk factors. 
The use of mechanical methods (IPC, GECS, PVP) 
should be associated with one of these pharmacologi-
cal methods described above, during hospitalization.
In the case of high risk of bleeding, IPC may be 
used, until one of the above drugs can be introduced, 
or as an adjuvant method, if the patient has already 
presented previous DVT.
The use of NFH or ASA is not indicated, as these 
methods are less effective and/or safe. 
total hip arthroplasty (tHA) 
According to the 2012 Guidelines of the 9th ACCP, 
prophylaxis with LMWH is recommended for at least 
four weeks, using the following: 
• enoxaparin 40 mg SC 1x daily, initiating up to 12 
hours pre- or postoperative. Or if the above is not 
possible:
• dalteparin 5.000ui SC 1x daily, initiating up to 12 
hours postoperative. 
• dabigatran 110 mg, oral route, initiated 1 to 4 hours 
postoperative, 24h after the first dose, two 110 mg 
tablets together. 
• rivaroxaban 10 mg, oral route, 1x daily, initiated 6 
to 12 hours postoperative.
• vitamin K blockers.
Graduated elastic compression stockings may be 
used (20-30 mmHg in the ankle) throughout this pe-
riod, in association with the pharmacological methods, 
decreasing still further the risk of VTE, as well as im-
proving the edema, facilitating walking.
Prophylaxis should be used for at least 10 to 14 
days, possibly extending to 35 days, depending on the 
associated risk factors. 
Knee arthroscopy
In less aggressive surgeries, such as knee arthros-
copy, the phenomenon of VTE can also be seen in stu-
dies using doppler US and venography in patients who 
have not received prophylaxis. These data suggest an 
incidence of 9.9% for total DVT and 2.1% for proximal 
DVT(35), which makes the analysis of the risk of VTE 
and eventual prophylaxis interesting in these patients 
too.  In young patients with no other risk factor for VTE, 
the only option should be early walking. No other me-
thod is indicated for prophylaxis in DVT.
For patients with some risk factor for VTE, or a com-
plicated procedure, prophylaxis should be discussed, 
whether mechanical or pharmacological, which may be 
continued in the patient’s home for up to seven days(39).
FINAL CONSIDERATIONS
Thromboprophylaxis may represent one of the 
greatest benefits to be offered to a patient who re-
quires – whether by choice or emergency – an or-
thopedic intervention, particularly arthroplasties of 
the lower limbs.
In an open analysis study of VTE in three years of 
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follow-up at a university hospital with 3300 surgeries 
and 15,000 patients treated annually, the incidence of 
VTE in the classical high-risk groups in hip fracture, 
THA and TKA were low, with approximately 0.6%, 
and that of pulmonary embolism of 0.27%, with two 
cases of death by pulmonary embolism, occurring on 
days 72 and 109 after surgery. Patients with hip frac-
tures had more VTE. The majority of cases of VTE 
occurred after discharge..
These data show us the importance of prophylaxis 
and its potential in the reduction of risks in ortho-
pedic patients.
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